Striving for sustainable growth beyond FY24

Company

17 Jan 2024 | 5 Min Read

Cipla focuses on sustainable growth beyond FY24 with a robust ANDA pipeline.

The company aims to enhance its prescription base and strengthen its generics and consumer healthcare businesses.

Cipla is developing difficult-to-manufacture products in the US generics segment.

Valued at 25x forward earnings, Cipla has a target price of INR1,540.

Cipla is a top pick in the large-cap pharma space due to its growth levers and pipeline.

The text provides cash flow statements and projections, showing inflows, outflows, and closing balances.